US Physicalrapy Net Worth
US Physicalrapy Net Worth Breakdown | USPH |
US Physicalrapy Net Worth Analysis
US Physicalrapy's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including US Physicalrapy's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of US Physicalrapy's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform US Physicalrapy's net worth analysis. One common approach is to calculate US Physicalrapy's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares US Physicalrapy's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing US Physicalrapy's net worth. This approach calculates the present value of US Physicalrapy's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of US Physicalrapy's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate US Physicalrapy's net worth. This involves comparing US Physicalrapy's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into US Physicalrapy's net worth relative to its peers.
Enterprise Value |
|
To determine if US Physicalrapy is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding US Physicalrapy's net worth research are outlined below:
| Over 98.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Bernard Harris of 1600 shares of US Physicalrapy subject to Rule 16b-3 |
US Physicalrapy Quarterly Good Will |
|
US Physicalrapy uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in US Physicalrapy. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to US Physicalrapy's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 28th of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know US Physicalrapy's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as US Physicalrapy is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading US Physicalrapy backward and forwards among themselves. US Physicalrapy's institutional investor refers to the entity that pools money to purchase US Physicalrapy's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-09-30 | 343.1 K | Riverbridge Partners Llc | 2024-09-30 | 336.1 K | Gw&k Investment Management, Llc | 2024-09-30 | 320 K | Envestnet Asset Management Inc | 2024-09-30 | 249.6 K | Northern Trust Corp | 2024-09-30 | 229.8 K | Fred Alger Management, Llc | 2024-09-30 | 172.3 K | Fmr Inc | 2024-09-30 | 164.5 K | Bank Of New York Mellon Corp | 2024-06-30 | 157.1 K | Bank Of America Corp | 2024-06-30 | 150.7 K | Morgan Stanley - Brokerage Accounts | 2024-06-30 | 2.4 M | Blackrock Inc | 2024-06-30 | 2.3 M |
Follow US Physicalrapy's market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.47 B.Market Cap |
|
Project US Physicalrapy's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.04 | 0.04 | |
| Return On Capital Employed | 0.08 | 0.15 | |
| Return On Assets | 0.01 | 0.01 | |
| Return On Equity | 0.03 | 0.03 |
When accessing US Physicalrapy's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures US Physicalrapy's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of US Physicalrapy's profitability and make more informed investment decisions.
Evaluate US Physicalrapy's management efficiency
US Physicalrapy has return on total asset (ROA) of 0.0424 % which means that it generated a profit of $0.0424 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0475 %, meaning that it created $0.0475 on every $100 dollars invested by stockholders. US Physicalrapy's management efficiency ratios could be used to measure how well US Physicalrapy manages its routine affairs as well as how well it operates its assets and liabilities. The US Physicalrapy's current Return On Capital Employed is estimated to increase to 0.15, while Return On Tangible Assets are projected to decrease to 0.04. As of now, US Physicalrapy's Total Current Assets are increasing as compared to previous years. The US Physicalrapy's current Non Currrent Assets Other is estimated to increase to about 3 M, while Net Tangible Assets are forecasted to increase to (245.4 M).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 45.97 | 48.27 | |
| Tangible Book Value Per Share | 2.32 | 2.44 | |
| Enterprise Value Over EBITDA | 19.19 | 20.15 | |
| Price Book Value Ratio | 2.78 | 4.71 | |
| Enterprise Value Multiple | 19.19 | 20.15 | |
| Price Fair Value | 2.78 | 4.71 | |
| Enterprise Value | 144.3 M | 151.5 M |
Effective leadership at US Physicalrapy drives its competitive edge in the market. Our analysis focuses on how this translates to financial performance and stock value.
Enterprise Value Revenue 2.4823 | Revenue 639.1 M | Quarterly Revenue Growth 0.12 | Revenue Per Share 42.489 | Return On Equity 0.0475 |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific US Physicalrapy insiders, such as employees or executives, is commonly permitted as long as it does not rely on US Physicalrapy's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases US Physicalrapy insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
US Physicalrapy Corporate Filings
F4 | 26th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 13th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 12th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
10Q | 8th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
US Physicalrapy Earnings per Share Projection vs Actual
US Physicalrapy Corporate Directors
| Mark Brookner | Independent Director | Profile | |
| Kathleen Gilmartin | Independent Director | Profile | |
| Clayton Trier | Independent Director | Profile | |
| Bernard Harris | Independent Director | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in US Physicalrapy. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in USPH Stock please use our How to Invest in US Physicalrapy guide.You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of US Physicalrapy. If investors know USPH will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about US Physicalrapy listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.24) | Dividend Share 1.75 | Earnings Share 0.88 | Revenue Per Share 42.489 | Quarterly Revenue Growth 0.12 |
The market value of US Physicalrapy is measured differently than its book value, which is the value of USPH that is recorded on the company's balance sheet. Investors also form their own opinion of US Physicalrapy's value that differs from its market value or its book value, called intrinsic value, which is US Physicalrapy's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because US Physicalrapy's market value can be influenced by many factors that don't directly affect US Physicalrapy's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between US Physicalrapy's value and its price as these two are different measures arrived at by different means. Investors typically determine if US Physicalrapy is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, US Physicalrapy's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.